Can Targeting Glucose Transporters Be a Therapeutic Strategy?
Given their pivotal role in cancer metabolism, GLUTs present a promising target for cancer therapy. Inhibitors of GLUT1, such as WZB117, have shown efficacy in reducing glucose uptake and inducing cell death in cancer cells. However, the ubiquitous expression of GLUT1 in normal tissues poses a challenge for selective targeting. Novel strategies, including the use of nanoparticles or antibody-drug conjugates, are being explored to enhance specificity and minimize off-target effects.
